Shoreline Biosciences

Executive Summary

Shoreline Biosciences is a private San Diego-based biotechnology company founded in 2020, pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. The company leverages its proprietary platform to develop off-the-shelf natural killer (iNK) and macrophage (iMAC) cell therapies aimed at treating cancer and other serious diseases. By combining iPSC technology with advanced gene editing, Shoreline aims to overcome the limitations of patient-specific cell therapies, such as high cost and manufacturing complexity, while enabling repeat dosing and combination therapy approaches. Though still in early preclinical and clinical stages, the company has garnered attention for its innovative approach to creating standardized, scalable allogeneic cell therapies. Its pipeline focuses on multiple hematologic and solid tumor indications, with lead programs in iNK cells for acute myeloid leukemia and B-cell malignancies, and iMACs for solid tumors. The company's strategy centers on building a broad portfolio of off-the-shelf cell therapies that can be delivered to patients on demand, potentially transforming the cell therapy landscape.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead iNK program60% success
• Q2 2026Presentation of preclinical data for iMAC program at major conference80% success
• Q4 2026Announcement of strategic partnership or collaboration for manufacturing or clinical development50% success